Industry

VAXNEUVANCE is the first new pneumococcal conjugate vaccine for pediatric populations to be recommended in almost a decade RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to include … [Read more…]

LOS ANGELES & SALT LAKE CITY–(BUSINESS WIRE)–Reviv3 Procare Company (OTCQB:RVIV) today announced that it has successfully completed the previously announced acquisition of substantially all assets of AXIL & Associated Brands, a leading provider of hearing protection and enhancement products. “This transaction expands our product portfolio across a much wider range of industries and significantly broadens … [Read more…]

NEW HYDE PARK, N.Y.–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: FOUR YOUNG CHILDREN RECEIVE COVID-19 VACCINE AT COHEN CHILDREN’S Americans have another tool in the fight against coronavirus disease 2019 (COVID-19) after the U.S. Food and Drug Administration granted emergency use authorization for Pfizer-BioNTech’s … [Read more…]

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today released its 2021 Corporate Sustainability / ESG Report entitled Better Takes Shape. Aptar’s 2021 Corporate Sustainability / ESG Report highlights activities across the Company’s global operations and summarizes milestones measured and … [Read more…]

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported results from a retrospective, matched case … [Read more…]

KAILUA KONA, Hawaii–(BUSINESS WIRE)–Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2022, ended March 31, 2022. Commenting on the fiscal year results (changes shown vs. fiscal 2021), Cyanotech’s Chief Executive Officer Emeritus and Chief Scientific … [Read more…]

LIVERMORE, Calif.–(BUSINESS WIRE)–Performant Financial Corporation (Nasdaq: PFMT) (“the Company”, “Performant”), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, today announced a new dba name, Performant Healthcare Solutions, which the Company will begin using immediately. There will be no changes to the Company’s ticker symbol nor to its corporate structure following this … [Read more…]

Also Hosts 25th Anniversary Employee Fundraiser with JA of Northern California to Help Raise Awareness of JA Across Align’s Global Organization TEMPE, Ariz.–(BUSINESS WIRE)–Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital … [Read more…]

Northwell’s Center for Gun Violence Prevention hosts survivors and advocates seeking solutions NEW HYDE PARK, N.Y.–(BUSINESS WIRE)–Northwell Health’s Center for Gun Violence Prevention on Tuesday brought together dozens of gun violence survivors, family members who have lost loved ones and advocates as part of an ongoing effort to build a coalition of support and public … [Read more…]

PHILADELPHIA–(BUSINESS WIRE)–In 2021, Blue Cross Blue Shield Plans’ costs declined by 0.4% per member compared with growth of 5.2% in 2020 and 6.6% in 2019. These comparisons are between continuously reporting Plans and eliminate the effect of product mix differences between comparison years. Median PMPM costs were $41.66. The results are published in Plan Management … [Read more…]